中文摘要 |
Benzbromarone為一有效降尿酸藥劑。26名健康男性口服100mg後所得血漿藥物動力學參數為:Cmax (3.51 ± 0.90μg/mL,mean ± SD),AUCt (0-14 h, 17.94 ± 4.53μg.h/mL) , total AUC (19.00 ± 4.73μg.h/mL),Tmax (3.08 ± 1.15 h) , terminal phase T1/2 (2.97 ± 0.85 h) , MRT (5.70 ± 1.25 h) and Cl/F (89.5 ± 26.2 mL/min) . Wagner-Nelson解析結果該藥在吸收過程中有代謝反應。若同時評量Cmax 和AUC,或其對數轉換向量,可得90%可信橢圓,若同時評量Cmax,AUC和MRT,或其對數轉換向量,可得90%可信橢圓球來描述互為相關的生體可用率參數的90%可信範園。比較benzbromarone在華人和白種人體內的藥物動力學參數值,並未發現有所差異。在本試驗也未發現在白種人中所具有的對該藥物呈消失遲緩的表型。" |
英文摘要 |
Pharmacokinetics of benzbromarone, a potent hypo-uricemics, have been investigated employing 26 normal Chinese males. Following oral administration of 100 mg dose (Desuric 100 mg/tablet, Labaz France), the pharmacokinetics of benzbromarone based on plasma data were Cmax (3.51 ± 0.90 µg/mL, mean± SD), AUCt (0-14 h, 17.94 ± 4.53 µg•h/mL), total AUC (19.00 ± 4.73 µg•h/mL), Tmax (3.08 ± 1.15 h), terminal phase T112 (2.97 ± 0.85 h), MRT (5.70 ± 1.25 h) and CI/F (89.5 ± 26.2 mL/min). Wagner-Nelson absorption plots of the mean benzbromarone plasma concentrations suggest that there are competing reactions in the absorption process. The 90% confidence regions for Cmax and AUC, and for Cmax, AUC and MRT, and their log-transformed vectors were also estimated. No evidence to show that the pharmacokinetics of benzbromarone in Chinese are different from those reported in Caucasian subjects, and none of the slow elimination phenotype with benzbromarone have been observed in this study.
Benzbromarone為一有效降尿酸藥劑。26名健康男性口服100mg後所得血漿藥物動力學參數為:Cmax (3.51 ± 0.90μg/mL,mean ± SD),AUCt (0-14 h, 17.94 ± 4.53μg.h/mL) , total AUC (19.00 ± 4.73μg.h/mL),Tmax (3.08 ± 1.15 h) , terminal phase T1/2 (2.97 ± 0.85 h) , MRT (5.70 ± 1.25 h) and Cl/F (89.5 ± 26.2 mL/min) . Wagner-Nelson解析結果該藥在吸收過程中有代謝反應。若同時評量Cmax 和AUC,或其對數轉換向量,可得90%可信橢圓,若同時評量Cmax,AUC和MRT,或其對數轉換向量,可得90%可信橢圓球來描述互為相關的生體可用率參數的90%可信範園。比較benzbromarone在華人和白種人體內的藥物動力學參數值,並未發現有所差異。在本試驗也未發現在白種人中所具有的對該藥物呈消失遲緩的表型。 |